Abstract
Get full access to this article
View all access options for this article.
References
1.Food and Drug Administration Broad Agency Announcement for the Advanced Research and Development of Regulatory Science . www.fbo.gov/index?s=opportunity&mode=form&id=80ccadceb97c7ee8941b383ed6791fb1&tab=core&_cview=0 (last accessed Nov. 6 , 2015
2.CFR—Code of Federal Regulations Title 21 . April 1 , 2105 . Subpart I—Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible . www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.9 (last accessed Nov. 6 , 2015
3.CFR—Code of Federal Regulations Title 21 . April 1 , 2105 . Subpart H—Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible . www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=601.90 (last accessed Nov. 6 , 2015
4.U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) . Product Development Under the Animal Rule: Guidance for Industry . October 2015 . www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf (last accessed Nov. 6 , 2015
5.U.S. Food and Drug Administration . Drug Development Tools (DDT) Qualification Programs . www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ (last accessed Nov. 5 , 2015